Introduction
Current therapy for the head and neck cancer utilizes an aggressive multimodal approach with surgery, radiotherapy, and chemotherapy, depending on the tumor stage and patient characteristics. Despite advances in the therapeutic approaches, no substantial improvement in efficacy and survival has occurred over the past several decades. Conventional palliative treatments, such as chemotherapy, are often toxic and sometimes ineffective. In addition, no effective salvage therapy is available for whom standard treatment fails. Therefore, new treatments are needed both to improve survival in the long term and to obtain worthwhile, less toxic palliation in the short term.
Recent progress in gene therapy technologies has made it possible to develop novel therapeutic strategies for intractable cancers. Head and neck cancer is particularly well suited for gene transduction strategies. First, its location in the upper aerodigestive tract allows easy access for vector delivery and assessment of response. Second, targeting of gene transduction can be achieved by direct injection of the vector into the tumor. Finally, metastases mostly occur late in head and neck cancer progression, making local disease responsible for most of the morbidity and mortality.
1,2 Therefore, any improvement in local disease control implies benefits for patients. At present, several virus vectors such as retroviral, adenoviral and adeno-associated virus (AAV) vectors 3, 4 have been utilized for the experiments of cancer gene therapy. AAV is a non-pathogenic virus with a single-stranded DNA genome. 5, 6 AAV vectors have emerged as a useful alternative to other vectors, 7 and AAV have been evaluated in preclinical and clinical models for cystic fibrosis, 8 Parkinson's disease 9 and Hemophilia B.
10 AAV vectors have a broad host range and can transduce head and neck cancer cells. 11 However, an obstacle to these applications is a low transgene expression efficiency, mainly due to a limited secondstrand synthesis. 12, 13 Recently, g-ray irradiation has been reported to enhance the second-strand synthesis of the AAV vector genome and improve the transgene expression. [14] [15] [16] In our previous study, we demonstrated that grays enhance AAV-mediated transgene expression in maxillary sinus cancer cells in vitro.
11 Thus, an AAV vector encoding suicide gene would kill target cells more efficiently when combined with g-ray irradiation therapy. Although the herpes simplex virus type-1 thymidine kinase (HSVtk)/ganciclovir (GCV) system has shown to be effective for controlling tumor growth in animal models, [17] [18] [19] [20] this therapeutic approach alone sometimes fails to eradicate cancer cells, and tumors recur thereafter. Thus, alternative therapeutic modalities, such as combination therapy should be considered. 21, 22 In this study, we demonstrate effective suicide gene therapy using the AAV vector in combination with g-ray irradiation, enhancing the antitumor activity both in vitro and in vivo.
Results
Comparison of the transduction efficiency of AAVLacZ between HeLa and HEp-2 cells Effect of g-ray irradiation on AAV-mediated transgene expression g-Rays have been shown to increase the transduction efficiency with AAV vectors, mainly by accelerating the rate of leading-strand synthesis of the AAV vector genome. According to our previous study, 11 optimal transduction efficiency was obtained when the cells were transduced with 1 Â 10 3 particles/cell of AAVLacZ immediately after irradiation. In Figure 2 , g-ray irradiation significantly increased LacZ expression in HeLa and HEp-2 cells in a dose-dependent manner. (one-way ANOVA: Po0.01).
g-Rays enhance the second-strand synthesis of the AAV genome in HeLa and HEp-2 cells
To examine whether the second-strand synthesis of the AAV vector genome occurs more efficiently in g-rayirradiated cells, HeLa and HEp-2 cells were subjected to AAV-mediated suicide gene therapy with g-ray irradiation T Kanazawa et al 0, 2, or 4 Gy of g-ray irradiation, and then transduced with 1 Â 10 4 particles/cell of AAVLacZ. Forty-eight hours after transduction, total DNA was isolated, treated with mung bean nuclease, and then loaded on 1% agarose gels. After transfer to nylon membranes, signals corresponding to the AAVLacZ genome were detected ( Figure 3 ). Mung bean nuclease was used to digest the single-stranded DNA and to clearly visualize the doublestranded replicative form (RF) of the AAV vector genome. The RF was almost equal to 4.7 kb fragment derived from pAAVLacZ in size. At the dose of 4 Gy, in both HeLa and HEp-2 cells, the intensity of signal corresponding to the RF increased significantly, suggesting that the augmented transgene expression was associated with the conversion of the AAV vector genome to the double-stranded RF. Figure 4 shows the killing effect of various concentrations of GCV on HeLa and HEp-2 cells transduced with 1 Â 10 5 particles/cell of recombinant AAV with HSVtk expression cassette (AAVtk) (closed bar). When the AAVtk-transduced cells were treated with 1 mg/ml of GCV, 75% of HeLa cells and 35% of HEp-2 cells were killed. As the concentration of GCV was increased, surviving cells were reduced and 98% of HeLa cells and 96% of HEp-2 cells were killed by exposure to 10 mg/ml of GCV, which was significantly higher than the killing rate in AAVLacZ-transduced cells (hatched bar) or mocktransduced cells (open bar) (two-way ANOVA: Po0.01). 4 particles/cell of AAVLacZ immediately after 0, 2, or 4 Gy of g-ray irradiation. Two days later, total DNA was isolated in a low-salt condition. After mung bean nuclease treatment, the DNA samples were loaded on 1% agarose gels, transferred onto nylon membranes (Hybond N + , Amersham), and then hybridized with a radiolabeled CMVspecific probe. Signals were detected by using an imaging analyzer. Lane 1, a 4.7 kb fragment derived from pAAVLacZ; lane 2, mock transduced; lanes 3-5, AAVLacZ-transduced immediately after 0-, 2-, or 4-Gy irradiation respectively. RF: the double-stranded replicative form. 
GCV treatment
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Enhanced cytocidal effect of the AAVtk/GCV system by g-ray irradiation
To facilitate comparison of the therapeutic outcome, the killing effect of GCV (3 mg/ml) on HeLa or HEp-2 cells transduced with various doses of AAVtk with or without g-ray irradiation was evaluated ( Figure 5 ). When HeLa and HEp-2 cells were transduced with 3 Â 10 4 particles/ cell of AAVtk without irradiation, 48% of the HeLa cells and 40% of the HEp-2 cells were killed by the exposure to the GCV. As the dose of AAVtk was increased, the number of surviving cells were reduced, and 98% of the HeLa cells and 95% of the HEp-2 cells were killed when transduced with 3 Â 10 5 particles/cell of AAVtk, which was significantly higher than the killing rate in the case of AAVLacZ-transduced cells as expected. To investigate whether g-ray enhances the killing effect of AAVtk/GCV, HeLa and HEp-2 cells were irradiated with 2 or 4 Gy of g-ray immediately before the transduction with various doses of AAVtk, and then cultured in 3 mg/ml of GCV. When the HeLa cells were transduced with 3 Â 10 4 particles/cell of AAVtk, 70% of the 2 Gy irradiated cells and 85% of the 4 Gy irradiated cells were killed by the addition of GCV. When the HeLa cells were transduced at 3 Â 10 5 particles/cell, g-ray irradiation enhanced the killing effects of AAVtk/GCV system by four-fold. g-Ray irradiation also enhanced the killing effects on HEp-2 cells by 15-fold. The enhancement by g-ray irradiation was calculated from the ratio of 4 Gy irradiated survival rate to non-irradiated survival rate. These results show that g-ray irradiation enhances the killing effects of AAVtk/GCV system significantly (two-way ANOVA: Po0.01).
g-Ray enhances the transgene expression in vivo
To assess the enhancement of transgene expression by gray irradiation in vivo, the AAVLacZ-transduced tumors were stained with X-gal ( Figure 6 ). Compared with nonirradiated control, the tumors irradiated at 4 Gy showed increased number of X-gal-positive cells. To quantify the amount of b-galactosidase, we homogenized the nonirradiated or 4 Gy irradiated tumors and measured with the b-gal ELISA kit. As shown in Figure 7 , the amount of b-galactosidase in 4 Gy irradiated tumors was 2.5 times larger than that in non-irradiated tumors (one-way ANOVA: Po0.01).
Suppressive effects of combination therapy upon tumor growth in vivo
To examine the killing effect of this system in vivo, tumor nodules were established in the flanks of BALB/c nude mice by subcutaneous injection of the HEp-2 cells. Once tumors were established, those animals were irradiated at 4 Gy and then directly injected with 1 Â 10 12 particles of AAVLacZ or AAVtk in the tumors. Administration of GCV (50 mg/kg) or phosphate-buffered saline (PBS) intraperitoneally twice a day was started at 24 h after the vector injection and continued for 2 weeks. The tumors were measured every 3 days.
Five treatment groups of 4 or 5 animals each were established: Group 1 is the AAVLacZ-transduced animals with PBS administration (n¼4). Group 2 is the AAVtk-transduced animals with GCV administration (n¼5). Group 3 is the AAVLacZ-transduced animals with 4 Gy irradiation and GCV administration (n¼5). Group 4 is the AAVtk-transduced animals with 4 Gy irradiation and PBS administration (n¼4). Group 5 is the AAVtk-transduced animals with 4 Gy irradiation and GCV administration.
The representative growth curve of the tumors after treatment is shown in Figure 8 . The AAVtk/GCV system suppressed the growth rate of xenografted tumors by 
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half, and g-ray irradiation augmented the antitumor activity five-fold as assessed by the relative tumor volume to the controls. The combined approach with AAVtk/GCV system and g-ray irradiation suppressed the tumor growth for 30 days. These data were analyzed by two-way ANOVA (Po0.01).
Discussion
In this study, we demonstrated that g-ray irradiation enhanced AAV vector-mediated transgene expression and cytocidal effect of AAVtk/GCV on target cells. These findings were also shown in animal experiments, ie g-ray irradiation enhanced transgene expression and killing effect of the AAVtk/GCV upon the grafted tumors.
There is a possibility that the killing effect was contributed by HSVtk/GCV and g-ray irradiation without AAV vectors. However, we made several experiments about the second-strand synthesis utilizing AAVLacZ and demonstrated that the enhanced killing effect can be explained by the higher conversion efficiency of AAV vector genome to double-stranded form. Although several studies have been reported on the higher conversion efficiency, the mechanism by which a genetic stress enhances the second-strand synthesis is not fully understood. [12] [13] [14] [15] [16] Qing et al reported that the enhancement of AAV vector transduction by UV and adenovirus E4orf6 correlated with induction of two distinct molecular conversion pathways, and UV led to increased abundance of circular AAV vector genome. Some studies have shown that DNA repair synthesis is required for efficient transduction rather than replicative cellular DNA synthesis.
13,25
The machinery of cellular DNA repair synthesis may play an important role in converting the single-stranded AAV vector genome to a double-stranded form, which is activated by g-ray irradiation. Several studies reported that AAV vectors were useful for the treatment of cancers in model experiments. Kunke et al 3 showed that expressing the antisense of human papillomavirus early gene effectively killed the tumors derived from cervical cancer cells. Suicide gene therapy, in particular, HSVtk-expressing AAV vectors, was reported in the application to several kinds of cancers. The AAV vectors expressing HSVtk and interleukin 2 effectively killed glioma cells implanted into brains of nude mice. 26 The expression of HSVtk driven by a liver-specific promoter via AAV vectors in tumors experimentally produced by implantation of hepatocellular carcinoma cells successfully retarded the tumor progression. 27 We previously demonstrated the enhancement of the cytocidal effect of AAVtk/GCV system by AAV-mediated suicide gene therapy with g-ray irradiation T Kanazawa et al g-ray in vitro. 11 The AAVtk/GCV system effectively killed the cancer cells depending on the concentration of GCV. Moreover, when the cancer cells were irradiated prior to transduction with AAVtk, they were killed more efficiently in a dose-dependent manner.
To extend these in vitro findings to an animal model, in the present study, we investigated the enhancement of AAV-mediated transgene expression by g-ray irradiation in nude mice. To confirm whether g-ray enhances the transgene expression, the xenografted tumors were injected with AAVLacZ. g-Ray irradiation increased the number of X-gal-positive cells and the amount of bgalactosidase as expected in the tumors in vivo. Furthermore, significantly higher growth inhibition of the xenografted tumors was observed in the 4 Gy irradiation plus AAVtk/GCV group compared with the AAVtk/ GCV system alone, the 4 Gy irradiation plus AAVLacZ/ GCV, or the AAVtk/PBS. The combination therapy using other vectors and irradiation has been reported, 21, 22 but the augmentation of the second-strand synthesis by g-ray irradiation is unique to AAV vectors.
Apoptosis induced by g-ray irradiation enhances the bystander effects, which may allow nearby untransduced cells to take up the apoptotic vesicles containing phosphorylated toxic GCV metabolites. 21 Thus, the combination therapy of AAV-mediated suicide gene therapy with radiotherapy or other genotoxic stress such as chemotherapy seems to be valuable for the treatment of cancers.
Recently, the HSVtk mutants with improved GCVmediated killing and bystander effect have been developed. [28] [29] [30] Since GCV has side effects such as pancytopenia 31 and acute renal failure, 32 the concentration of GCV should be kept as low as possible. In this study, the concentration of GCV was higher than the standard experiments, this concentration was chosen because the difference in the killing effects was most prominent among the groups, and the animals well tolerated throughout the study.
Our model would be another alternative to improve AAV-mediated suicide gene therapy of cancer. Although several studies were reported on combining radiotherapy and viral vector mediated gene therapy, 22 ,33 our therapeutic model made it with lower dose of irradiation. AAV-mediated suicide gene therapy and g-ray irradiation may provide a more effective and safer alternative for the treatment of head and neck cancer.
Materials and methods
Cell lines
To compare the transgene expression between head and neck cancer cells and the cells used in the standard experiments, we used HeLa cells other than the head and neck cancer cells. HeLa cells and a human laryngeal carcinoma cell line, HEp-2 cells (a gift from the Cell Resource Center for Biomedical Research, Tohoku University), were cultured in DMEM/F12 (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% heatinactivated fetal bovine serum, 100 U/ml of penicillin and 100 mg/ml of streptomycin (Irvine Scientific, Santa Ana, CA, USA) at 371C in 5% CO 2 .
Plasmids
The plasmid pAAVLacZ contains the cytomegalovirus (CMV) promoter, human growth hormone first intron, E. coli LacZ gene, and SV40 early polyadenylation sequence between two inverted terminal repeats. A 1.8 kb DNA fragment encoding the HSVtk gene was obtained by double digestion with Hinc II and Pvu II of plasmid M2 34 (a gift from Dr Y Mishina, Yokohama City University, Japan) and subcloned into the pAAVLacZ in the place of the LacZ gene (pAAVtk). pW1909 is an AAV helper plasmid harboring rep/cap sequences, in which the p5 promoter was moved to downstream of the poly A signal to enhance AAV vector production. 35 An adenovirus helper plasmid plAd5 contains the adenovirus early genes: E2a, E4, and VA. 36 AAV vector production AAV vectors were produced based on the plasmid transfection. 36 Briefly, subconfluent 293 cells were cotransfected with AAV vector plasmid, pW1909, and adenovirus helper plasmid by a calcium phosphate precipitation method. Recombinant AAV was harvested by three cycles of freeze/thaw. The vector solution was then purified twice on a CsCl gradient as described previously. 36 The vector titer was determined by a quantitative dot blot hybridization of DNase-treated stocks. 
AAV-mediated suicide gene therapy with g-ray irradiation
T Kanazawa et al
Transduction of HeLa or HEp-2 cells with AAV vectors
One day before transduction, 1 Â 10 5 cells were plated onto 3.5 cm dishes in triplicate. The cells were transduced with different amounts of AAVLacZ.
Assay for b-galactosidase activity
Thirty-six hours after transduction with AAVLacZ, the cells were fixed by 0.05% glutaraldehyde in PBS and stained with X-gal (Takara, Tokyo, Japan) in PBS containing 5 mM K 3 [Fe(CN) 6 ], 5 mM K 4 [Fe(CN) 6 ], and 1 mM MgCl 2 . 37 For each dish, 500 cells were counted by light microscopy and the percentage of blue stained cells was determined. An average of three wells was determined for each variable. In addition, the amount of b-galactosidase was quantified by using the b-gal ELISA kit (Boehringer-Mannheim, Hilden, Germany).
The enhancement of transgene expression by g-ray irradiation
To examine whether g-ray enhances the transgene expression in HeLa and HEp-2 cells, the cells were plated at a density of 1 Â 10 5 cells/well in six-well culture plates 24 h prior to irradiation at doses of 0-5 Gy. Irradiation was done using GAMMACELL-40 (Atomic Energy of Canada, Ottawa, Canada) at a dose rate of 0.83 Gy/min. The cells were then transduced with 1 Â 10 3 particles/cell of AAVLacZ immediately after irradiation. Thirty-six hours after transduction, we measured the amount of b-galactosidase with the b-gal ELISA.
Analysis of the second-strand synthesis of the vector genome
HeLa and HEp-2 cells grown in 10 cm dishes (1 Â 10 6 / dish) were transduced with 1 Â 10 4 particles/cell of AAVLacZ immediately after irradiation. Two days later, total DNA was isolated under a low-salt condition (10 mM Tris-HCl [pH 7.5], 5mM EDTA, and 0.5% sodium dodecyl sulfate) to prevent annealing of the AAVLacZ genomes. 38 Forty micrograms of genomic DNA digested with 80 units of mung bean nuclease (Takara, Tokyo, Japan) was resolved on 1% agarose gels, transferred to nylon membranes (Hybond N + ; Amersham, Buckinghamshire, UK) and then hybridized with CMV promoter-specific probe radiolabeled with random primer labeling kit (Amersham, Buckinghamshire, UK) in 50% formamide, 6 Â SSC, 0.5% SDS, 5 Â Denhardt's solution, and 100 mg/ml of denatured salmon sperm DNA at 421C overnight. The membranes were washed, and then analyzed by using an image analyzer (BAS-1500, Fuji, Tokyo, Japan).
GCV treatment
The cells were plated and transduced with AAVtk at the dose of 1 Â 10 5 particles/cell. Twenty-four hours after transduction with AAV vectors, culture media were replaced by fresh media containing various concentrations of GCV ranging from 0 to 10 mg/ml. After a 7-day incubation in the presence of GCV, surviving cells were counted. The survival rate was calculated from the ratio of the number of surviving cells to the number of cells not treated with GCV. To evaluate the synergistic effect of the AAVtk/GCV system and g-ray irradiation, the cells were irradiated at doses of 2 or 4 Gy just before AAV vector transduction.
Animal experiments
Female BALB/c nude mice (between 4 and 5 weeks of age) were purchased from CLEA Japan, Inc. (Tokyo, Japan) and maintained in the specific pathogen-free animal facility at Jichi Medical School. The HEp-2 cells (2 Â 10 6 /mouse) with 25% Matrigel (Collaborative Research, Bedford, MA, USA) were injected subcutaneously into the flanks of the mice. The tumors were irradiated by the GAMMACELL-40.
Assay for b-galactosidase in tumors
To examine whether g-rays enhance the transgene expression in vivo, 5 Â 10 11 particles of AAVLacZ were injected into the tumors in a diameter of 4-5 mm immediately after 4 Gy irradiation. Three days after AAVLacZ was injected, the tumors were excised from mice and frozen in OTC embedding compound on a liquid-nitrogen bath. Cryostat sections (20 mm thick) were made with a Cryotome CR-502 (Nakagawa, Tokyo, Japan) and were fixed with 0.05% glutaraldehyde in PBS. Histochemical staining for b-galactosidase activity was performed in the sections, as described above and counterstained with nuclear fast red. Furthermore, to quantify the amount of b-galactosidase in the nonirradiated or 4 Gy irradiated tumor, these samples were homogenized for 10 s in a tissue homogenizer. The homogenates were centrifuged twice and aliquots of the supernatants were prepared for the assay with b-gal ELISA kit (Boehringer-Mannheim). Four mice were used in each treatment group.
In vivo gene therapy
To examine the tumor growth inhibition, 1 Â 10 12 particles of AAVtk or AAVLacZ as control were injected into the tumors immediately after 4 Gy irradiation. Administration of GCV (50 mg/kg) or PBS intraperitoneally twice a day was started 24 h after the virus infection and continued for 2 weeks. The tumors were measured every 3 days with calipers in two perpendicular diameters. The tumor volume was calculated as 0.5 Â L ÂW 2 , where L is the length (mm) and W is the width (mm). 39 The tumors reaching a diameter of 4-5 mm were used as the starting point for the study of tumor growth or regression.
